Unknown

Dataset Information

0

EAPH-03. FINAL RESULTS OF THE PHASE II, SINGLE ARM TRIAL OF IRINOTECAN AND CISPLATIN IN CHILDREN WITH HIGH-RISK GLIAL TUMORS.


ABSTRACT: AbstractWe conducted an open label, single arm phase II clinical trial with with irinotecan and cisplatin (I/C) for pediatric patients with glial tumors (EudraCT:2009-010742-59).METHODSPatients diagnosed with high-risk (HR) gliomas at diagnosis (HGG, ependymomas, DIPG, or HR-LGG) received sixteen weekly outpatient iv. cycles of Cisplatin(30mg/m2) and Irinotecan(65mg/m2). Malignant gliomas received radiation at progression. Objective response was assessed with MRI plus volumetric analysis. Clinical and neurological changes were assessed.RESULTSSince November/2009 until December/2012, 39 patients (66,7% females), aged 7m-17y (mean=84-months), diagnosed with DIPG(n=7), HGG(n=5), anaplastic-ependymoma(n=6), atypical neurocytoma(n=1), LGG n=20: Pilocytic Astrocytoma(n=7), Pilomyxoid A.(n=1), Astrocytoma NOS(n=5), Grade-II astrocytoma (n=2), Ganglioglioma(n=2), LGG-NF1(n=3) were included. Most frequent events were nausea/vomiting, mostly grade 1–2, only 5/39 grade >2; 17 patients (43,6%) developed grade-1 diarrhea. At the end of follow-up 3/31 patients developed hypoacusia, all grade 1 (9,7%). Five (45.5%) patients with HGG, 1 relapsed HGG(100%), 7 DIPG(100%) and 3 LGG(15.0%) progressed during treatment, ending prematurely the study. Objective response rate (ORR) at the end of therapy (week 21), was by ITT / PP, of 54,4% for HGG, 0% for DIPG, and 85% for HR-LGG After a median follow-up time of 67.5 months, OS/EFS was 0/0% for relapsed HGG and DIPG, 62%/23% for High-grade glial tumors, and 95%/43% for HR-LGG. Radiation was avoided in 19/20 HR-LGG patients.CONCLUSIONThe I/C regimen was acceptably tolerated and shows activity for some children with HR-gliomas, mainly HR-LGG.

SUBMITTER: Cruz O 

PROVIDER: S-EPMC6012024 | BioStudies | 2018-01-01

SECONDARY ACCESSION(S): 2009-010742-59

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4218260 | BioStudies
1000-01-01 | S-EPMC4677415 | BioStudies
1000-01-01 | S-EPMC5355046 | BioStudies
2013-01-01 | S-EPMC3579804 | BioStudies
1000-01-01 | S-EPMC3922515 | BioStudies
2019-01-01 | S-EPMC6838935 | BioStudies
1000-01-01 | S-EPMC5334387 | BioStudies
2020-01-01 | S-EPMC7239884 | BioStudies
2018-01-01 | S-EPMC6866325 | BioStudies
2016-01-01 | S-EPMC4881971 | BioStudies